Phase I study of artificial tumor-antigens (GPC3/AFP/MAGE1) pulsed dendritic cell vaccination for patients with hepatocellular carcinoma
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2016
Price : $35 *
At a glance
- Drugs Tumour peptide-loaded dendritic cell vaccine Tella (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Tella
- 26 Sep 2016 Status changed from recruiting to completed.
- 24 Mar 2014 Planned End Date 1 Jun 2014 as reported by University Hospital Medical Information Network - Japan.
- 06 Oct 2013 New trial record